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nstimulated PMN remains in a resting state, with critical
omponents of its antimicrobial machinery segregated into
ifferent subcellular compartments. Upon exposure to sol-
ble host factors, microbial products, or microbes, the PMN
henotype rapidly transforms; ﬁrst ingesting the microbe
nd thereby sequestering it in the phagosome, and then
ecruiting and activating a variety of responses targeted
o kill and degrade the trapped microbe. This presenta-
ion aims to discuss some of the mechanisms underlying
peciﬁc features of the PMN response within the context
f innate immune response to and resolution of infec-
ion. Concomitant with PMN activation, membrane-bound
ranule compartments fuse with the nascent phagosome,
hereby delivering enzymes as well as antimicrobial pep-
ides directly to the microbe. Concurrently, the NADPH
xidase is assembled and activated at the phagosome mem-
rane, generating reactive oxygen species that directly and
ndirectly contribute to microbial killing and degradation.
ollectively, these orchestrated responses of the PMN cre-
te an intraphagosomal environment inhospitable to the
hagocytosed microbe. The mechanisms underlying the gen-
ration and antimicrobial action of several bioactive species
ill be highlighted, as will the speciﬁc synergies between
oluble circulating proteins and PMN responses that collabo-
ate to eradicate invading microbes. PMN contribute to host
efense in ways other than those directly associated with
hagocytosis, as they release IL-8 and other chemokines to
ecruit additional immune cells to the fray and to modu-
ate the antimicrobial activities of resident cells at the site
f infection. Lastly, PMN direct biochemical and cellular
vents that contribute to the subsequent resolution of the
nﬂammatory response, an essential step in returning to a
omeostatic, resting state.
oi:10.1016/j.ijid.2008.05.120
ommunity-Acquired MRSA: What in the World is Going
n? (invited)
2.001
he Origin and Evolution of MRSA
. Kreiswirth
Public Health Research Institute, New Jersey, NJ, USA
ince the identiﬁcation of the ﬁrst methicillin resistant S.
ureus (MRSA) isolate in 1961, there is extensive litera-
ure on its successful spread in the nosocomial setting, its
ncremental rise in antibiotic resistance and more recently,
ts emergence as a community associated pathogen spread-
ng in otherwise healthy populations. Extensive genotyping
f S. aureus, including genome sequencing of six MRSA
trains, and determining the organization of the staphylo-
occal chromosomal cassettes that harbor the methicillin
esistance gene, mecA, have identiﬁed six major pandemic
lones that have spread along epidemic waves, consistent
ith the historic outbreaks caused by penicillin resistant in
he 1950s. The current epidemic strain, commonly referred
o as USA300, has aggressively spread across the United
tates causing an inordinate number of skin and soft tissue
nfections in diverse healthy populations ranging from chil-
ren to senior citizens. Comparative genomic sequencing of
t
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0 chosen USA300 isolates representative of different types
f infections and from different regions of the US revealed
he molecular scars of an epidemic strain that is rapidly
hanging. This lecture will discuss S. aureus epidemic waves
nd the current emergence of community associated MRSA.
oi:10.1016/j.ijid.2008.05.121
2.002
vasion of Innate Host Defense by Staphylococcus aureus
. DeLeo
Laboratory of Human Bacterial Pathogenesis, NIAID,
amilton, MT, USA
uman polymorphonuclear leukocytes (PMNs or neutrophils)
re essential to the innate immune response against invading
icroorganisms. Although most bacteria are killed readily
y PMNs, pathogens such as Staphylococcus aureus have
volved multiple mechanisms to circumvent destruction by
eutrophils and thereby cause human infections. Notably,
rominent community-associated methicillin-resistant S.
ureus (CA-MRSA) strains have enhanced ability to evade
illing by human PMNs and rapidly destroy these crit-
cal innate immune cells. CA-MRSA immune evasion is
ultifactorial and includes resistance to antimicrobial pep-
ides, detoxiﬁcation of neutrophil reactive oxygen species,
roduction of cytolytic molecules, and reprogramming of
ormal neutrophil apoptosis or turnover. Collectively, the
urrent data indicate enhanced CA-MRSA virulence is linked
o evasion of killing by neutrophils, which likely underlies
at least in part) the ability of prominent CA-MRSA strains to
ause disease in individuals without known risk factors for
nfection.
oi:10.1016/j.ijid.2008.05.122
2.003
icrobial Pathogenesis of Community-Acquired MRSA
nfections
.J. Foster
Trinity College Dublin, Dublin, Ireland
taphylococcus aureus is a commensal of the anterior nares.
t permanently colonizes the moist squamous epithelium of
bout 20% of the population and intermittently colonizes
nother 60%. Several different bacterial surface proteins
romote adhesion to desquamated nasal epithelial cells.
lumping factor B and iron-regulated surface determinant
sdA have been shown to stimulate efﬁcient colonization of
he nares of rodents, and in the case of ClfB, humans. ClfB
inds to host cytokeratin 10 which is exposed on the surface
f desquamated epithelial cells. When S.aureus breeches
he skin it can cause both localized and invasive infections.
he bacterium can express a plethora of surface-located
nd secreted molecules that promote infection. Surface pro-
eins promote adhesion of bacteria to host cells and tissues.
urface polysaccharides and proteins help the bacterium
o evade innate immune responses by inhibiting phagocy-
osis by neutrophils. The organism secretes proteins that
an intefere with neutrophil migration and with complement
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ﬁxation which reduces the level of opsonins. It can co-opt
host proteases to destroy opsonins on the bacterial surface.
Several different pore-forming toxins are secreted, some of
which destroy neutrophils (alpha-toxin and Panton Valen-
tine Leucocidin). If taken up by phagocytic cells S.aureus
can resist intracellular killing mechanisms such as lysozyme,
free oxygen radicals and antimicrobial peptides. S.aureus
can secrete proteins called superantigens which trigger the
activation of T cells in a manner that lacks the speciﬁcity of
antigen presentation. This causes depletion of immune cells
and the failure to mount a robust response with immunolog-
ical memory and may help explain the recurrent nature of
infections. This presentation will review current knowledge
of the phenomena of colopnization and disease pathogen-
esis gathered from studies with many strains of S.aureus.
Reference will be made to CA-MRSA where appropriate.
doi:10.1016/j.ijid.2008.05.123
52.004
Clinical Aspects of the Community-Acquired MRSA
Epidemic
H. Chambers
University of California San Francisco, San Francisco, CA,
USA
Prevalence of methicillin-resistant Staphylococcus
aureus(MRSA) in the community is high and rising both
in the United States and in other countries. USA300 and
USA400, are the predominant community-associated MRSA
(CA-MRSA) clones circulating in US communities. Enhanced
transmissibility and ﬁtness, and hypervirulence characterize
and probably drive emergence of MRSA in the community.
The burden of disease caused by MRSA in the community
exceeds that occurring in hospitals. In addition, community
strains of MRSA are now a major cause of hospital-onset
infections. Identiﬁcation of multiple-drug resistant vari-
ants of community MRSA strains is of particular concern.
Emergence of CA-MRSA has a profound impact on choice of
therapy for treatment of all staphylococcal infections. For
those treated as out-patients, clinicians must increasingly
rely on second line agents, often in the absence of good data
supporting their effectiveness. For hospitalized patients, an
inevitable consequence is even greater use of vancomycin.
This will increase the already considerable pressure for
selection of vancomycin non-susceptible strains. Use of
vancomycin will likely be accompanied by a higher rate of
treatment failure. Several alternative drugs are available
for treatment of MRSA, but none of these has yet been
shown to be superior to vancomycin. The search for new
approaches to prevention and treatment of staphylococcal
infections has never been more important.
doi:10.1016/j.ijid.2008.05.124
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artnering in R&D to Develop New Drugs for the Most
eglected Diseases (invited)
3.001
verview Abstract for the Symposium: Partnering in R&D
o develop new drugs for the most neglected diseases
escription: Tropical diseases such as chloroquine-resistant
alaria, leishmaniasis, lymphatic ﬁlariasis, Chagas disease,
uman African trypanosomiasis (HAT), dengue fever, and
chistosomiasis continue to cause signiﬁcant morbidity and
ortality worldwide. With few new treatments that tend to
e unaffordable and poorly adapted to the ﬁeld, physicians
re forced to use old tropical medicines that are increas-
ngly ineffective due to inevitable drug resistance. Together
ith tuberculosis and HIV/AIDS, these disabling and/or life-
hreatening diseases represent an enduring unmet medical
eed and are collectively called ‘‘neglected diseases’’.
Of the 1,556 new drugs approved between 1975 and 2004,
nly 21 (1.3%) were speciﬁcally developed for tropical dis-
ases and tuberculosis, even though these diseases account
or 11.4% of the global disease burden. With exponential
rogress made in the basic knowledge of many infectious
iseases, it is ironic that the drugs currently used to treat
inetoplastid diseases were discovered decades ago. With
ew exceptions, the wealth of basic research knowledge of
hese parasites is not being translated into practical appli-
ations.
Although the R&D landscape has signiﬁcantly changed for
eglected diseases since 2000, the need remains for new
eld-adapted drugs for the kinetoplastid diseases. Founded
n 2003 to address the needs of patients with these most
eglected diseases, DNDi (Drugs for Neglected Diseases
nitiative) is a collaborative, patients’ needs-driven, not-
or-proﬁt drug R&D organization that is currently developing
ew treatments against sleeping sickness (human African
rypanosomiasis, HAT), visceral leishmaniasis (VL), Chagas
isease, and malaria.
The only way to improve control is to develop innovative
ew drugs and diagnostics and ensure they are available to
atients. This symposium aims to review the opportunities
nd challenges ahead in the different phases of research and
evelopment of new drugs for the most neglected diseases.
oi:10.1016/j.ijid.2008.05.125
xtensively Drug-Resistant TB: NewName or New Problem
invited)
4.001
he Epidemiology of XDR TB in KwaZulu Natal South
frica: A New name or a New Problem
. Rustomjee ∗, A. Pym
Medical Research Council, Durban, South Africa
ntroduction: The description of the AIDS-related ‘‘Tugela
erry’’ Outbreak (TFO) of XDR TB in KwaZulu Natal focused
nternational attention on this province of South Africa as
n epicenter of an XDR TB epidemic of unknown proportion.
imilarly the global burden of TB drug-resistance, particu-
arly in countries with the highest incidence of HIV and TB is
